Le Tanno Pauline, Folacci Mathilde, Revilloud Jean, Faivre Laurence, Laurent Gabriel, Pinson Lucile, Amedro Pascal, Millat Gilles, Janin Alexandre, Vivaudou Michel, Roux-Buisson Nathalie, Fauré Julien
Université Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Grenoble, France.
CEA, CNRS, Institut de Biologie Structurale, Université Grenoble Alpes, Grenoble, France.
Front Genet. 2021 Nov 25;12:773177. doi: 10.3389/fgene.2021.773177. eCollection 2021.
Andersen-Tawil Syndrome (ATS) is a rare disease defined by the association of cardiac arrhythmias, periodic paralysis and dysmorphic features, and is caused by loss-of-function mutations. However, when extracardiac symptoms are atypical or absent, the patient can be diagnosed with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), a rare arrhythmia at high risk of sudden death, mostly due to mutations. The identification of variants in CPVT suspicion is very rare but important because beta blockers, the cornerstone of CPVT therapy, could be less efficient. We report here the cases of two patients addressed for CPVT-like phenotypes. Genetic investigations led to the identification of p. Arg82Trp and p. Pro186Gln variants in the gene Functional studies showed that both variants forms of Kir2.1 monomers act as dominant negative and drastically reduced the activity of the tetrameric channel. We characterize here a new pathogenic variant (p.Pro186Gln) of gene and highlight the interest of accurate cardiologic evaluation and of attention to extracardiac signs to distinguish CPVT from atypical ATS, and guide therapeutic decisions. We also confirm that the gene must be investigated during CPVT molecular analysis.
安德森-陶威尔综合征(ATS)是一种罕见疾病,其定义为心律失常、周期性麻痹和畸形特征相关联,由功能丧失性突变引起。然而,当心脏外症状不典型或不存在时,患者可被诊断为儿茶酚胺能多形性室性心动过速(CPVT),这是一种罕见的心律失常,猝死风险高,主要也是由突变导致。在疑似CPVT中鉴定变异非常罕见但很重要,因为β受体阻滞剂作为CPVT治疗的基石,可能效果欠佳。我们在此报告两名表现出类似CPVT表型患者的病例。基因研究发现了该基因中的p.Arg82Trp和p.Pro186Gln变异。功能研究表明,Kir2.1单体的这两种变异形式均起显性负性作用,并大幅降低四聚体通道的活性。我们在此鉴定了该基因的一种新的致病变异(p.Pro186Gln),强调了准确的心脏评估以及关注心脏外体征以区分CPVT与非典型ATS并指导治疗决策的重要性。我们还证实,在CPVT分子分析期间必须对该基因进行检测。